98 related articles for article (PubMed ID: 20132901)
1. PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ.
Lubbers LS; Rowe BA; Hodge LM; Browne SE; Gundersdorf R; Jones P; Hess FJ; Reynolds IJ
J Pharmacol Toxicol Methods; 2010; 61(3):319-28. PubMed ID: 20132901
[TBL] [Abstract][Full Text] [Related]
2. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
3. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
[TBL] [Abstract][Full Text] [Related]
4. A scintillation proximity assay for poly(ADP-ribose) polymerase.
Cheung A; Zhang J
Anal Biochem; 2000 Jun; 282(1):24-8. PubMed ID: 10860495
[TBL] [Abstract][Full Text] [Related]
5. Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia.
Nagayama T; Simon RP; Chen D; Henshall DC; Pei W; Stetler RA; Chen J
J Neurochem; 2000 Apr; 74(4):1636-45. PubMed ID: 10737622
[TBL] [Abstract][Full Text] [Related]
6. Increased poly(ADP-ribosyl)ation in peripheral leukocytes and the reperfused myocardium tissue of rats with ischemia/reperfusion injury: prevention by 3-aminobenzamide treatment.
Zhang LQ; Qi GX; Jiang DM; Tian W; Zou JL
Shock; 2012 May; 37(5):492-500. PubMed ID: 22266967
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
Genovese T; Mazzon E; Muià C; Patel NS; Threadgill MD; Bramanti P; De Sarro A; Thiemermann C; Cuzzocrea S
J Pharmacol Exp Ther; 2005 Feb; 312(2):449-57. PubMed ID: 15452194
[TBL] [Abstract][Full Text] [Related]
8. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
9. Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Brown JA; Marala RB
J Pharmacol Toxicol Methods; 2002; 47(3):137-41. PubMed ID: 12628304
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
Obrosova IG; Minchenko AG; Frank RN; Seigel GM; Zsengeller Z; Pacher P; Stevens MJ; Szabó C
Int J Mol Med; 2004 Jul; 14(1):55-64. PubMed ID: 15202016
[TBL] [Abstract][Full Text] [Related]
11. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
13. Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase.
Koedel U; Winkler F; Angele B; Fontana A; Pfister HW
J Cereb Blood Flow Metab; 2002 Jan; 22(1):39-49. PubMed ID: 11807392
[TBL] [Abstract][Full Text] [Related]
14. A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.
Iwashita A; Mihara K; Yamazaki S; Matsuura S; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Sep; 310(3):1114-24. PubMed ID: 15113847
[TBL] [Abstract][Full Text] [Related]
15. In situ staining for poly(ADP-ribose) polymerase activity using an NAD analogue.
Davis RE; Mysore V; Browning JC; Hsieh JC; Lu QA; Katsikis PD
J Histochem Cytochem; 1998 Nov; 46(11):1279-89. PubMed ID: 9774627
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Chiarugi A
Br J Pharmacol; 2002 Nov; 137(6):761-70. PubMed ID: 12411406
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Abdelkarim GE; Gertz K; Harms C; Katchanov J; Dirnagl U; Szabó C; Endres M
Int J Mol Med; 2001 Mar; 7(3):255-60. PubMed ID: 11179503
[TBL] [Abstract][Full Text] [Related]
19. AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Liu M; Li Z; Chen GW; Li ZM; Wang LP; Ye JT; Luo HB; Liu PQ
Mol Cell Endocrinol; 2014 Jul; 392(1-2):14-22. PubMed ID: 24859603
[TBL] [Abstract][Full Text] [Related]
20. Caspase-1 and poly (ADP-ribose) polymerase inhibitors may protect against peroxynitrite-induced neurotoxicity independent of their enzyme inhibitor activity.
Zhang Y; Rosenberg PA
Eur J Neurosci; 2004 Oct; 20(7):1727-36. PubMed ID: 15379993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
